Abingdon Health plc (LSE:ABDX) has held the official opening of its Manufacturing hub in Madison, Wisconsin, a site the company says will support the expansion of its US contract development and manufacturing business. The announcement contains no financial figures.
What was announced
On 25 September 2026, Abingdon Health announced the official opening of its manufacturing Facility in Madison, Wisconsin. The event took the form of a ribbon-cutting ceremony attended by company executives and local and state officials.
The company said the hub gives it the infrastructure and capacity to expand its US footprint and to respond to what it describes as growing Demand for high-quality, rapidly deployable diagnostic testing solutions developed and "Made in the USA".
The announcement does not state when the Madison site was acquired or established, the size of the facility, its production capacity, the number of staff employed there, or the Capital cost of fitting it out. No grants or public funding, customer contracts or regulatory approvals linked to the site are mentioned.
Who attended
The opening was attended by several elected officials and public representatives. Abingdon Health named Congressman Mark Pocan, who represents Wisconsin's 2nd Congressional District; Madison Mayor Satya Rhodes-Conway; and John Miller, Secretary of the Wisconsin Economic Development Corporation (WEDC). Also listed were Wisconsin Assembly Representative Lisa Subeck and Jose Rodriguez, from the office of Wisconsin Senate minority leader Dianne Hesselbein, along with other representatives of the Wisconsin State Legislature.
From the company, attendees included Chris Yates, President of Abingdon Health USA and Chief Commercial Officer of the group, and Tanya Quint, Site Lead at Abingdon Health USA Inc.
Mr Yates said: "The opening of our Madison manufacturing hub is a significant milestone for Abingdon Health USA that enables us to offer a more comprehensive and integrated 'end to end' CDMO solution for our US customers, paving the way for continued growth in the biggest med-tech market in the world." The reference to continued growth is a statement of the company's ambition rather than a quantified target.
Background
Abingdon Health describes itself as a contract development and manufacturing organisation (CDMO) for lateral flow diagnostic tests and other med-tech products, meaning it develops and manufactures products on behalf of client businesses. Its services include product development, regulatory strategy, technology transfer and manufacturing. The company says it serves customers across a range of sectors, including infectious disease, clinical testing, companion diagnostics, animal health and environmental testing.
The group was founded in 2008 and is headquartered in York, England. It also has facilities in Doncaster, England, and now in Madison, Wisconsin. The company links the Madison hub to demand for diagnostic testing solutions that are developed and manufactured in the United States.
What to watch next
Because the announcement is limited to the opening itself, it does not indicate how quickly the Madison hub will contribute to Revenue or when it will reach any particular level of utilisation. Investors looking for that information will need to wait for future trading updates or results, where the company may report on the site's contribution, customer wins in the US and any associated costs.
Other points to watch include whether Abingdon Health (LSE:ABDX) announces US customer contracts served from Madison, any regulatory registrations for products manufactured at the site, and further detail on staffing and capacity. The company has not provided guidance on any of these matters in this release, and no timetable for further updates on the site was given.






Please wait processing your request...